Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Alcohol Clin Exp Res. 2021 Apr;45(4):709-719. doi: 10.1111/acer.14581. Epub 2021 Apr 20.
Alcoholic hepatitis (AH) is a severe and life-threatening alcohol-associated liver disease. Only a minority of heavy drinkers acquires AH and severity varies among affected individuals, suggesting a genetic basis for the susceptibility to and severity of AH.
A cohort consisting of 211 patients with AH and 176 heavy drinking controls was genotyped for five variants in five candidate genes that have been associated with chronic liver diseases: rs738409 in patatin-like phospholipase domain-containing protein 3 (PNPLA3), rs72613567 in hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13), rs58542926 in transmembrane 6 superfamily member 2 (TM6SF2), rs641738 in membrane bound O-acyltransferase domain containing 7 (MBOAT7), and a copy number variant in the haptoglobin (HP) gene. We tested the effects of individual variants and the combined/interacting effects of variants on AH risk and severity.
We found significant associations between AH risk and the risk alleles of rs738409 (p = 0.0081) and HP (p = 0.0371), but not rs72613567 (p = 0.3132), rs58542926 (p = 0.2180), or rs641738 (p = 0.7630), after adjusting for patient's age and sex. A multiple regression model indicated that PNPLA3 rs738409:G [OR = 1.59 (95% CI: 1.15-2.22), p = 0.0055] and HP*2 [OR = 1.38 (95% CI: 1.04-1.82), p = 0.0245], when combined and adjusted for age and sex also had a large influence on AH risk among heavy drinkers. In the entire cohort, variants in PNPLA3 and HP were associated with increased total bilirubin and Model for End-stage Liver Disease (MELD) score, both measures of AH severity. The HSD17B13 rs72613567:AA allele was not found to reduce risk of AH in patients carrying the G allele of PNPLA3 rs738409 (p = 0.0921).
PNPLA3 and HP genetic variants increase AH risk and are associated with total bilirubin and MELD score, surrogates of AH severity.
酒精性肝炎(AH)是一种严重且危及生命的酒精相关肝病。只有少数大量饮酒者会患上 AH,而且受影响个体的严重程度也各不相同,这表明 AH 的易感性和严重程度存在遗传基础。
一项由 211 名 AH 患者和 176 名大量饮酒对照者组成的队列,对五个候选基因中的五个变体进行了基因分型,这些候选基因与慢性肝病有关:载脂蛋白样磷脂酶域 3(PNPLA3)中的 rs738409、羟甾类 17-β 脱氢酶 13(HSD17B13)中的 rs72613567、跨膜 6 超家族成员 2(TM6SF2)中的 rs58542926、膜结合酰基转移酶域包含 7(MBOAT7)中的 rs641738 和 haptoglobin(HP)基因中的一个拷贝数变异。我们测试了个体变体以及变体的组合/相互作用效应对 AH 风险和严重程度的影响。
我们发现 AH 风险与 rs738409(p=0.0081)和 HP(p=0.0371)的风险等位基因之间存在显著关联,但 rs72613567(p=0.3132)、rs58542926(p=0.2180)或 rs641738(p=0.7630)则没有关联,这是在调整了患者的年龄和性别之后的结果。多元回归模型表明,PNPLA3 rs738409:G[OR=1.59(95% CI:1.15-2.22),p=0.0055]和 HP*2[OR=1.38(95% CI:1.04-1.82),p=0.0245],当与年龄和性别相结合并进行调整时,对大量饮酒者的 AH 风险也有很大影响。在整个队列中,PNPLA3 和 HP 中的变体与总胆红素和终末期肝病模型(MELD)评分升高有关,这两个指标都是 AH 严重程度的衡量标准。在携带 PNPLA3 rs738409 G 等位基因的患者中,HSD17B13 rs72613567:AA 等位基因并未被发现降低 AH 的风险(p=0.0921)。
PNPLA3 和 HP 遗传变异增加了 AH 的风险,并与总胆红素和 MELD 评分相关,这两个评分是 AH 严重程度的替代指标。